"Building on Edwards' 40 years of leadership in tissue valve technology, the INSPIRIS valve featuring RESILIA tissue has been in development for more than a decade and may be uniquely suited for future valve-in-valve procedures," said Bernard Zovighian, Edwards' corporate vice president, surgical heart valve therapy. "In partnership with surgeons, Edwards is committed to continually developing transformative surgical innovations that benefit patients."

Plans are underway for a full U.S. launch of the INSPIRIS valve in early 2018. The valve became commercially available in Europe earlier this year.

About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com and follow us on Twitter @EdwardsLifesci.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Drs. Puskas and Bavaria and Mr. Zovighian and expectations regarding the product's potential benefits and risks, as well as expected future innovations. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unanticipated outcomes of expanded and longer term clinical experience with the product, or unanticipated manufacturing, quality, development or regulatory delays or issues. These and other additional factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. These filings, along with important safety information about our products, may be found at www.edwards.com.

Cardiology Homepage